Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection
Bariola et al.,
Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with..,
medRxiv, doi:10.1101/2021.03.25.21254322 (Preprint)
Retrospective 234 patients receiving bamlanivimab and 234 matched controls, showing lower hospitalization and mortality with treatment. Greater benefit was seen with administration within 4 days of their positive COVID-19 test.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, VanBlargan].
risk of death, 66.8% lower, RR 0.33, p = 0.05, treatment 4 of 234 (1.7%), control 12 of 234 (5.1%), NNT 29, odds ratio converted to relative risk.
|
risk of death/hospitalization, 64.3% lower, RR 0.36, p < 0.001, treatment 16 of 234 (6.8%), control 45 of 234 (19.2%), NNT 8.1, odds ratio converted to relative risk, primary outcome.
|
risk of hospitalization, 60.7% lower, RR 0.39, p = 0.001, treatment 15 of 234 (6.4%), control 39 of 234 (16.7%), NNT 9.8, odds ratio converted to relative risk.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Bariola et al., 30 Mar 2021, retrospective, USA, preprint, 22 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.03.25.21254322; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
1
Impact of monoclonal antibody treatment on hospitalization and mortality among non-
2
hospitalized adults with SARS-CoV-2 infection
3
4
Authors: J. Ryan Bariola MD1, Erin K. McCreary PharmD1, Richard J. Wadas MD2, Kevin E.
5
Kip PhD3, Oscar C. Marroquin MD3, Tami Minnier MSN, RN4, Stephen Koscumb BS3, Kevin
6
Collins BS3, Mark Schmidhofer MD5, Judith A. Shovel BSN RN4, Mary Kay Wisniewski, MT
7
MA COM4, Colleen Sullivan MHA6, Donald M. Yealy MD2, David A Nace MD MPH7, David
8
T. Huang MD MPH2,8,9, Ghady Haidar MD1, Tina Khadem PharmD1, Kelsey Linstrum MS6,9,
9
Christopher W. Seymour MD MSc6,9, Stephanie K. Montgomery MS6,9, Derek C. Angus MD
10
MPH FRCP6,8,9, Graham M. Snyder MD SM1
11
1. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of
12
13
14
Medicine, Pittsburgh, PA, USA
2. Department of Emergency Medicine, University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA
15
3. Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
16
4. Wolff Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
17
5. Division of Cardiology, Dept of Medicine, University of Pittsburgh School of Medicine,
18
Pittsburgh, PA, USA
19
6. UPMC Health System Office of Healthcare Innovation, Pittsburgh, PA, USA
20
7. Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh,
21
22
23
Pittsburgh, PA, USA
8. Department of Critical Care Medicine, University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2021.03.25.21254322; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
24
9. Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center,
25
Department of Critical Care Medicine, University of Pittsburgh School of Medicine,
26
Pittsburgh, PA, USA
27
28
Corresponding Author:
29
Graham M. Snyder, MD SM
30
Address: 3601 Fifth Avenue, Suite 150, Pittsburgh, PA 15213
31
Phone/Fax: 412-647-6718/412-692-2768
32
Email: snydergm3@upmc.edu
33
Keywords: COVID-19, SARS-CoV-2, monoclonal antibodies, bamlanivimab, etesevimab,
34
casirivimab, imdevimab
35
2
medRxiv preprint doi: https://doi.org/10.1101/2021.03.25.21254322; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
36
ABSTRACT
37
Background: Monoclonal antibody (mAb) treatment may prevent complications of COVID-19.
38
We sought to quantify the impact of bamlanivimab monotherapy on hospitalizations and
39
mortality, as well as Emergency..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit